- Home
- ADC vs ABVX Comparison
ADC vs ABVX Comparison
Compare ADC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADC
- ABVX
- Stock Information
- Founded
- ADC 1971
- ABVX 2013
- Country
- ADC United States
- ABVX France
- Employees
- ADC N/A
- ABVX 69
- Industry
- ADC Real Estate Investment Trusts
- ABVX
- Sector
- ADC Real Estate
- ABVX
- Exchange
- ADC Nasdaq
- ABVX Nasdaq
- Market Cap
- ADC 7.9B
- ABVX 6.7B
- IPO Year
- ADC 1994
- ABVX N/A
- Fundamental
- Price
- ADC $70.36
- ABVX $86.72
- Analyst Decision
- ADC Buy
- ABVX Strong Buy
- Analyst Count
- ADC 12
- ABVX 9
- Target Price
- ADC $81.45
- ABVX $94.11
- AVG Volume (30 Days)
- ADC 861.9K
- ABVX 969.2K
- Earning Date
- ADC 10-21-2025
- ABVX 08-11-2025
- Dividend Yield
- ADC 4.36%
- ABVX N/A
- EPS Growth
- ADC N/A
- ABVX N/A
- EPS
- ADC 1.68
- ABVX N/A
- Revenue
- ADC $659,753,000.00
- ABVX $7,073,400.00
- Revenue This Year
- ADC $15.42
- ABVX $4.44
- Revenue Next Year
- ADC $10.73
- ABVX N/A
- P/E Ratio
- ADC $41.89
- ABVX N/A
- Revenue Growth
- ADC 13.16
- ABVX N/A
- 52 Week Low
- ADC $67.58
- ABVX $4.77
- 52 Week High
- ADC $79.65
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- ADC 39.71
- ABVX 68.69
- Support Level
- ADC $70.43
- ABVX $81.90
- Resistance Level
- ADC $71.83
- ABVX $90.70
- Average True Range (ATR)
- ADC 0.83
- ABVX 2.75
- MACD
- ADC -0.07
- ABVX -0.69
- Stochastic Oscillator
- ADC 17.16
- ABVX 61.24
About ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.